Form 4: United Therapeutics CEO Executes Option-Related Stock Sales

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, exercised stock options and sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options at an exercise price of $146.03 per share on March 3, 2026.
• Concurrently, Rothblatt sold 9,500 shares of common stock at weighted average prices ranging from $491.6827 to $507.0903 per share on the same date.
• These transactions were executed as part of a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Rothblatt directly owns 130 shares of common stock.
• Indirect beneficial ownership includes 166 shares by spouse, 324,518 shares by family trusts where Rothblatt shares investment power, 258,117 shares by family trusts where spouse is trustee, 45,596 shares by family trusts where spouse shares investment power, and 10,962 shares by family trusts where Rothblatt is sole trustee.
• The 10b5-1 plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options (all expiring March 17, 2027) or December 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and personal financial planning under a pre-arranged 10b5-1 plan, with no direct positive or negative implications for the company's operational performance or immediate stock valuation.

Future Outlook

The filing details a pre-arranged trading plan for future option exercises and sales, indicating a planned disposition of a significant number of options. The plan covers the exercise of up to 1,734,410 stock options until December 31, 2026, or their expiration on March 17, 2027.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives to manage personal finances and diversify holdings without concerns of trading on material non-public information. These plans are typically set up in advance and do not necessarily reflect a change in management's outlook on the company's future performance.

Stakeholder Impact

• Shareholders: The sale represents a diversification of holdings by a key executive, which is a routine event under a 10b5-1 plan and generally has minimal direct impact on other shareholders.

Next Steps

• Continued exercise of up to 1,734,410 stock options under the 10b5-1 plan.
• Potential further sales of common stock resulting from option exercises under the same plan.

Key Dates

Recommendation

The filing reports a routine insider transaction (exercise of options and sale of shares) executed under a pre-arranged 10b5-1 trading plan. Such transactions are generally for personal financial management and diversification, and do not typically signal a change in the company's fundamentals or future prospects. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Martine A. Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale